Respira Therapeutics, Inc.
Respira Therapeutics is developing next-generation cardiopulmonary disease-targeted inhalation products. Their advanced particle engineering and formulation approaches, combined with proprietary device technologies, aim to enhance drug delivery to the lung periphery. The company is pioneering respiratory therapies for patients with pulmonary arterial hypertension (PAH), providing acute relief from symptoms such as breathlessness and fatigue. Their lead drug-device product candidate, RT234-PAH, is a first-in-class inhaled therapy intended for 'as-needed' use by patients. They are conducting Phase 2B clinical trials for this pipeline candidate.
Industries
Nr. of Employees
small (1-50)
Respira Therapeutics, Inc.
Patents
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US-12263174-B2
View DetailsMethods and compositions for treatment of pulmonary hypertension and other lung disorders
US-11491160-B2
View DetailsMethods and compositions for treatment of pulmonary hypertension and other lung disorders
US-11491161-B2
View Details
Methods and compositions for treatment of pulmonary hypertension and other lung disorders
US-12263174-B2
View DetailsMethods and compositions for treatment of pulmonary hypertension and other lung disorders
US-11491160-B2
View DetailsMethods and compositions for treatment of pulmonary hypertension and other lung disorders
US-11491161-B2
View DetailsProducts
Lead inhaled drug-device candidate for pulmonary arterial hypertension (unnamed)
A drug-device combination intended as an inhaled, 'as-needed' therapy developed to provide acute relief of breathlessness and improve exercise-related parameters in pulmonary arterial hypertension; advanced in Phase 2 clinical testing.
Published technical posters and peer-reviewed studies
Collection of scientific publications and conference posters on DPI design, aerosol performance, formulation strategies, and clinical PK/safety for inhaled drugs.
Lead inhaled drug-device candidate for pulmonary arterial hypertension (unnamed)
A drug-device combination intended as an inhaled, 'as-needed' therapy developed to provide acute relief of breathlessness and improve exercise-related parameters in pulmonary arterial hypertension; advanced in Phase 2 clinical testing.
Published technical posters and peer-reviewed studies
Collection of scientific publications and conference posters on DPI design, aerosol performance, formulation strategies, and clinical PK/safety for inhaled drugs.
Services
End-to-end development support including formulation, device design, early clinical safety/PK studies, and Phase 2 trial execution for inhaled drug-device candidates.
In vitro aerosol characterization across flow rates and in vivo deposition feasibility studies in human subjects.
Development of spray-dried and coated particle formulations paired with inhaler prototypes to optimize peripheral lung delivery and reduce upper-airway deposition.
End-to-end development support including formulation, device design, early clinical safety/PK studies, and Phase 2 trial execution for inhaled drug-device candidates.
In vitro aerosol characterization across flow rates and in vivo deposition feasibility studies in human subjects.
Development of spray-dried and coated particle formulations paired with inhaler prototypes to optimize peripheral lung delivery and reduce upper-airway deposition.
Expertise Areas
- Pulmonary drug delivery
- Dry powder inhaler design
- Inhalation formulation development
- Aerosol performance and deposition studies
Key Technologies
- Dry powder inhaler (DPI) architectures
- Spray-drying for inhalation powders
- Particle engineering for aerosol control
- Phospholipid-based particle formulations
News & Updates
Respira Therapeutics announced the first patient has been dosed in their Phase 2b trial of RT234 for pulmonary arterial hypertension (PAH).
Respira is focused on developing next-generation inhalation products targeting cardiopulmonary diseases, with a focus on pulmonary arterial hypertension.
Respira Therapeutics announced the first patient has been dosed in their Phase 2b trial of RT234 for pulmonary arterial hypertension (PAH).
Respira is focused on developing next-generation inhalation products targeting cardiopulmonary diseases, with a focus on pulmonary arterial hypertension.